Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial.
Ryan CW, Tangen CM, Heath EI, Stein MN, Meng MV, Alva AS et al.
Lancet 2023; 402: 1043-1051.
Some 1545 patients were randomly assigned 10 mg of oral Everolimus daily or placebo for 54 weeks. 5-year recurrence-free survival was improved from 63 to 67 per cent (P=0.051), but this did not meet the prespecified P value for significance. Patients with more advanced disease benefitted most.
Comment: Not effective for most.
6 December 2023
Read paperAcademy
Part of the charitable activity of the Foundation, BJS Academy is an online educational resource for current and future surgeons.
The Academy is comprised of five distinct sections: Continuing surgical education, Young BJS, Cutting edge, Scientific surgery and Surgical news. Although the majority of this is open access, additional content is available to BJS subscribers and strategic partners.
